25 XP   0   0   10

Pharming Group NV
Buy, Hold or Sell?

Let's analyse Pharming together

PenkeI guess you are interested in Pharming Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharming Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.

Quick analysis of Pharming (30 sec.)










What can you expect buying and holding a share of Pharming? (30 sec.)

How much money do you get?

How much money do you get?
$0.03
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$3.38
Expected worth in 1 year
$3.63
How sure are you?
62.5%

+ What do you gain per year?

Total Gains per Share
$0.28
Return On Investment
2.6%

For what price can you sell your share?

Current Price per Share
$10.84
Expected price per share
$10 - $13.20
How sure are you?
50%

1. Valuation of Pharming (5 min.)




Live pricePrice per Share (EOD)

$10.84

Intrinsic Value Per Share

$-7.10 - $4.57

Total Value Per Share

$-3.72 - $7.94

2. Growth of Pharming (5 min.)




Is Pharming growing?

Current yearPrevious yearGrowGrow %
How rich?$227m$200.2m$19.9m9.1%

How much money is Pharming making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m$7.1m-$13.2m-216.7%
Net Profit Margin-11.5%14.1%--

How much money comes from the company's main activities?

3. Financial Health of Pharming (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#235 / 1031

Most Revenue
#123 / 1031

Most Profit
#497 / 1031

Most Efficient
#496 / 1031

What can you expect buying and holding a share of Pharming? (5 min.)

Welcome investor! Pharming's management wants to use your money to grow the business. In return you get a share of Pharming.

What can you expect buying and holding a share of Pharming?

First you should know what it really means to hold a share of Pharming. And how you can make/lose money.

Speculation

The Price per Share of Pharming is $10.84. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharming.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharming, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.38. Based on the TTM, the Book Value Change Per Share is $0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharming.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.050.5%-0.08-0.7%0.111.0%0.080.8%-0.010.0%
Usd Book Value Change Per Share0.151.4%0.060.6%0.100.9%0.121.1%0.090.8%
Usd Dividend Per Share0.000.0%0.010.1%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.151.4%0.070.6%0.100.9%0.121.1%0.090.8%
Usd Price Per Share11.40-11.90-9.13-6.65-3.32-
Price to Earnings Ratio55.29-42.87-39.52--7.20--3.60-
Price-to-Total Gains Ratio74.01--83.48-338.72-75.03-75.03-
Price to Book Ratio3.37-3.69-3.19-2.19-1.09-
Price-to-Total Gains Ratio74.01--83.48-338.72-75.03-75.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.84
Number of shares92
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.060.12
Usd Total Gains Per Share0.070.12
Gains per Quarter (92 shares)6.4311.46
Gains per Year (92 shares)25.7445.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13231614536
25464219182
3869682136128
41192942181174
5141151203226220
6161381463272266
7191611724317312
8221841984362358
9252072245407404
10272302505453450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%9.03.00.075.0%17.03.00.085.0%22.018.00.055.0%22.037.00.037.3%
Book Value Change Per Share3.01.00.075.0%7.03.02.058.3%14.04.02.070.0%25.013.02.062.5%31.022.06.052.5%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.058.01.7%
Total Gains per Share3.01.00.075.0%7.03.02.058.3%14.04.02.070.0%25.013.02.062.5%31.022.06.052.5%

Fundamentals of Pharming

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Fundamental data was last updated by Penke on 2024-03-09 19:12:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Pharming Group NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharming earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Net Profit Margin of 5.2% means that $0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharming Group NV:

  • The MRQ is 5.2%. The company is making a profit. +1
  • The TTM is -11.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ5.2%TTM-11.5%+16.7%
TTM-11.5%YOY14.1%-25.6%
TTM-11.5%5Y11.6%-23.1%
5Y11.6%10Y-63.0%+74.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2%-171.8%+177.0%
TTM-11.5%-205.8%+194.3%
YOY14.1%-262.1%+276.2%
5Y11.6%-455.6%+467.2%
10Y-63.0%-589.0%+526.0%
1.1.2. Return on Assets

Shows how efficient Pharming is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • 0.7% Return on Assets means that Pharming generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharming Group NV:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -1.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.7%TTM-1.3%+2.1%
TTM-1.3%YOY1.7%-3.1%
TTM-1.3%5Y1.8%-3.2%
5Y1.8%10Y-2.1%+4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-12.5%+13.2%
TTM-1.3%-12.2%+10.9%
YOY1.7%-11.2%+12.9%
5Y1.8%-13.4%+15.2%
10Y-2.1%-14.7%+12.6%
1.1.3. Return on Equity

Shows how efficient Pharming is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • 1.5% Return on Equity means Pharming generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharming Group NV:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -2.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.5%TTM-2.8%+4.3%
TTM-2.8%YOY3.4%-6.2%
TTM-2.8%5Y4.7%-7.5%
5Y4.7%10Y-23.5%+28.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-15.8%+17.3%
TTM-2.8%-15.7%+12.9%
YOY3.4%-13.9%+17.3%
5Y4.7%-18.3%+23.0%
10Y-23.5%-19.2%-4.3%

1.2. Operating Efficiency of Pharming Group NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharming is operating .

  • Measures how much profit Pharming makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • An Operating Margin of 7.4% means the company generated $0.07  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharming Group NV:

  • The MRQ is 7.4%. The company is operating less efficient.
  • The TTM is -5.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ7.4%TTM-5.8%+13.3%
TTM-5.8%YOY17.1%-23.0%
TTM-5.8%5Y20.3%-26.2%
5Y20.3%10Y-27.6%+47.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4%-299.1%+306.5%
TTM-5.8%-210.1%+204.3%
YOY17.1%-279.7%+296.8%
5Y20.3%-459.9%+480.2%
10Y-27.6%-596.9%+569.3%
1.2.2. Operating Ratio

Measures how efficient Pharming is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.97 means that the operating costs are $0.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pharming Group NV:

  • The MRQ is 0.971. The company is less efficient in keeping operating costs low.
  • The TTM is 1.062. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.971TTM1.062-0.091
TTM1.062YOY0.890+0.172
TTM1.0625Y0.812+0.250
5Y0.81210Y1.336-0.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9712.861-1.890
TTM1.0623.193-2.131
YOY0.8903.615-2.725
5Y0.8125.560-4.748
10Y1.3367.396-6.060

1.3. Liquidity of Pharming Group NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharming is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.29 means the company has $4.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharming Group NV:

  • The MRQ is 4.287. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.433. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.287TTM4.433-0.147
TTM4.433YOY5.322-0.889
TTM4.4335Y3.847+0.586
5Y3.84710Y3.068+0.779
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2873.986+0.301
TTM4.4334.440-0.007
YOY5.3225.552-0.230
5Y3.8476.158-2.311
10Y3.0686.492-3.424
1.3.2. Quick Ratio

Measures if Pharming is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Quick Ratio of 5.60 means the company can pay off $5.60 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharming Group NV:

  • The MRQ is 5.598. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.174. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.598TTM4.174+1.424
TTM4.174YOY4.669-0.495
TTM4.1745Y3.469+0.705
5Y3.46910Y2.536+0.933
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5983.638+1.960
TTM4.1744.168+0.006
YOY4.6695.515-0.846
5Y3.4696.012-2.543
10Y2.5366.209-3.673

1.4. Solvency of Pharming Group NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharming assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharming to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52 means that Pharming assets are financed with 51.9% credit (debt) and the remaining percentage (100% - 51.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharming Group NV:

  • The MRQ is 0.519. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.525. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.519TTM0.525-0.006
TTM0.525YOY0.500+0.026
TTM0.5255Y0.559-0.033
5Y0.55910Y0.633-0.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5190.335+0.184
TTM0.5250.330+0.195
YOY0.5000.267+0.233
5Y0.5590.367+0.192
10Y0.6330.378+0.255
1.4.2. Debt to Equity Ratio

Measures if Pharming is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Debt to Equity ratio of 107.9% means that company has $1.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharming Group NV:

  • The MRQ is 1.079. The company is able to pay all its debts with equity. +1
  • The TTM is 1.107. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.079TTM1.107-0.028
TTM1.107YOY1.000+0.106
TTM1.1075Y1.312-0.205
5Y1.31210Y2.887-1.575
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0790.376+0.703
TTM1.1070.398+0.709
YOY1.0000.334+0.666
5Y1.3120.429+0.883
10Y2.8870.476+2.411

2. Market Valuation of Pharming Group NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pharming generates.

  • Above 15 is considered overpriced but always compare Pharming to the Biotechnology industry mean.
  • A PE ratio of 55.29 means the investor is paying $55.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharming Group NV:

  • The EOD is 52.574. Based on the earnings, the company is expensive. -2
  • The MRQ is 55.290. Based on the earnings, the company is expensive. -2
  • The TTM is 42.874. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD52.574MRQ55.290-2.716
MRQ55.290TTM42.874+12.416
TTM42.874YOY39.519+3.354
TTM42.8745Y-7.202+50.076
5Y-7.20210Y-3.601-3.601
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD52.574-2.643+55.217
MRQ55.290-2.418+57.708
TTM42.874-2.742+45.616
YOY39.519-4.123+43.642
5Y-7.202-6.257-0.945
10Y-3.601-6.478+2.877
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharming Group NV:

  • The EOD is 53.880. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 56.664. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 29.260. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD53.880MRQ56.664-2.783
MRQ56.664TTM29.260+27.404
TTM29.260YOY26.258+3.002
TTM29.2605Y17.637+11.623
5Y17.63710Y8.818+8.818
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD53.880-3.244+57.124
MRQ56.664-2.939+59.603
TTM29.260-3.478+32.738
YOY26.258-5.592+31.850
5Y17.637-8.473+26.110
10Y8.818-8.881+17.699
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharming is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.37 means the investor is paying $3.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharming Group NV:

  • The EOD is 3.208. Based on the equity, the company is fair priced.
  • The MRQ is 3.373. Based on the equity, the company is fair priced.
  • The TTM is 3.687. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.208MRQ3.373-0.166
MRQ3.373TTM3.687-0.314
TTM3.687YOY3.195+0.492
TTM3.6875Y2.188+1.499
5Y2.18810Y1.094+1.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2082.124+1.084
MRQ3.3732.041+1.332
TTM3.6872.118+1.569
YOY3.1952.915+0.280
5Y2.1883.682-1.494
10Y1.0944.114-3.020
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pharming Group NV.

3.1. Institutions holding Pharming Group NV

Institutions are holding 0.068% of the shares of Pharming Group NV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Orion Portfolio Solutions, LLC0.01780.001611715117150
2023-09-30Morgan Stanley - Brokerage Accounts0.00380250000
Total 0.02160.001614215+11715+82.4%

3.2. Funds holding Pharming Group NV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Fidelity Nasdaq Composite Index0.00320.0002209300
Total 0.00320.0002209300.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pharming Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1540.062+147%0.098+57%0.123+25%0.085+80%
Book Value Per Share--3.3793.229+5%2.875+18%2.531+34%1.473+129%
Current Ratio--4.2874.433-3%5.322-19%3.847+11%3.068+40%
Debt To Asset Ratio--0.5190.525-1%0.500+4%0.559-7%0.633-18%
Debt To Equity Ratio--1.0791.107-3%1.000+8%1.312-18%2.887-63%
Dividend Per Share---0.007-100%-0%0.001-100%0.001-100%
Eps--0.052-0.079+254%0.109-53%0.084-39%-0.005+110%
Free Cash Flow Per Share--0.0500.013+298%0.115-56%0.152-67%0.086-41%
Free Cash Flow To Equity Per Share--0.1280.024+427%0.103+24%0.126+2%0.112+15%
Gross Profit Margin---6.253-6.2490%-3.493-44%0.267-2442%0.542-1254%
Intrinsic Value_10Y_max--4.565--------
Intrinsic Value_10Y_min---7.101--------
Intrinsic Value_1Y_max--0.438--------
Intrinsic Value_1Y_min--0.165--------
Intrinsic Value_3Y_max--1.331--------
Intrinsic Value_3Y_min---0.259--------
Intrinsic Value_5Y_max--2.242--------
Intrinsic Value_5Y_min---1.510--------
Market Cap714548952.000-7%766095595.200811739533.100-6%636164168.840+20%450403692.938+70%225201846.469+240%
Net Profit Margin--0.052-0.115+321%0.141-63%0.116-55%-0.630+1312%
Operating Margin--0.074-0.058+178%0.171-57%0.203-63%-0.276+471%
Operating Ratio--0.9711.062-9%0.890+9%0.812+20%1.336-27%
Pb Ratio3.208-5%3.3733.687-9%3.195+6%2.188+54%1.094+208%
Pe Ratio52.574-5%55.29042.874+29%39.519+40%-7.202+113%-3.601+107%
Price Per Share10.840-5%11.40011.895-4%9.133+25%6.645+72%3.323+243%
Price To Free Cash Flow Ratio53.880-5%56.66429.260+94%26.258+116%17.637+221%8.818+543%
Price To Total Gains Ratio70.370-5%74.006-83.475+213%338.723-78%75.034-1%75.034-1%
Quick Ratio--5.5984.174+34%4.669+20%3.469+61%2.536+121%
Return On Assets--0.007-0.013+283%0.017-57%0.018-60%-0.021+390%
Return On Equity--0.015-0.028+285%0.034-55%0.047-67%-0.235+1644%
Total Gains Per Share--0.1540.070+120%0.098+57%0.125+24%0.086+79%
Usd Book Value--227094261.400220205725.375+3%200208067.050+13%171482913.023+32%99473674.203+128%
Usd Book Value Change Per Share--0.1540.062+147%0.098+57%0.123+25%0.085+80%
Usd Book Value Per Share--3.3793.229+5%2.875+18%2.531+34%1.473+129%
Usd Dividend Per Share---0.007-100%-0%0.001-100%0.001-100%
Usd Eps--0.052-0.079+254%0.109-53%0.084-39%-0.005+110%
Usd Free Cash Flow--3380000.000926500.000+265%8014250.000-58%10241752.444-67%5769957.149-41%
Usd Free Cash Flow Per Share--0.0500.013+298%0.115-56%0.152-67%0.086-41%
Usd Free Cash Flow To Equity Per Share--0.1280.024+427%0.103+24%0.126+2%0.112+15%
Usd Market Cap714548952.000-7%766095595.200811739533.100-6%636164168.840+20%450403692.938+70%225201846.469+240%
Usd Price Per Share10.840-5%11.40011.895-4%9.133+25%6.645+72%3.323+243%
Usd Profit--3464000.000-6119250.000+277%7141250.000-51%5822118.770-41%-200851.379+106%
Usd Revenue--66661000.00057700000.000+16%48970000.000+36%52469415.037+27%33169988.904+101%
Usd Total Gains Per Share--0.1540.070+120%0.098+57%0.125+24%0.086+79%
 EOD+4 -4MRQTTM+27 -9YOY+14 -205Y+17 -1910Y+25 -11

4.2. Fundamental Score

Let's check the fundamental score of Pharming Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1552.574
Price to Book Ratio (EOD)Between0-13.208
Net Profit Margin (MRQ)Greater than00.052
Operating Margin (MRQ)Greater than00.074
Quick Ratio (MRQ)Greater than15.598
Current Ratio (MRQ)Greater than14.287
Debt to Asset Ratio (MRQ)Less than10.519
Debt to Equity Ratio (MRQ)Less than11.079
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.007
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.900
Ma 20Greater thanMa 5011.273
Ma 50Greater thanMa 10011.715
Ma 100Greater thanMa 20011.739
OpenGreater thanClose10.800
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Net Debt  -53,56738,011-15,556-28,413-43,96919,913-24,056142,320118,264
Total Other Income Expense Net -1,249-6,656-7,9050-7,9055,504-2,4014,1871,786



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets436,467
Total Liabilities226,525
Total Stockholder Equity209,942
 As reported
Total Liabilities 226,525
Total Stockholder Equity+ 209,942
Total Assets = 436,467

Assets

Total Assets436,467
Total Current Assets291,737
Long-term Assets144,730
Total Current Assets
Cash And Cash Equivalents 54,653
Short-term Investments 142,912
Net Receivables 40,521
Inventory 53,439
Other Current Assets 212
Total Current Assets  (as reported)291,737
Total Current Assets  (calculated)291,737
+/-0
Long-term Assets
Property Plant Equipment 37,482
Goodwill 3,779
Long Term Investments 9,239
Intangible Assets 66,070
Long-term Assets Other 1,552
Long-term Assets  (as reported)144,730
Long-term Assets  (calculated)118,122
+/- 26,608

Liabilities & Shareholders' Equity

Total Current Liabilities68,058
Long-term Liabilities158,467
Total Stockholder Equity209,942
Total Current Liabilities
Short-term Debt 5,518
Short Long Term Debt 1,748
Accounts payable 62,540
Other Current Liabilities 5,219
Total Current Liabilities  (as reported)68,058
Total Current Liabilities  (calculated)75,025
+/- 6,967
Long-term Liabilities
Long term Debt 129,733
Capital Lease Obligations Min Short Term Debt26,986
Long-term Liabilities  (as reported)158,467
Long-term Liabilities  (calculated)156,719
+/- 1,748
Total Stockholder Equity
Common Stock7,650
Retained Earnings -262,776
Accumulated Other Comprehensive Income -10,915
Other Stockholders Equity 475,983
Total Stockholder Equity (as reported)209,942
Total Stockholder Equity (calculated)209,942
+/-0
Other
Capital Stock7,650
Cash and Short Term Investments 197,565
Common Stock Shares Outstanding 67,201
Current Deferred Revenue-5,219
Liabilities and Stockholders Equity 436,467
Net Debt 109,332
Net Invested Capital 341,423
Net Working Capital 223,679
Property Plant and Equipment Gross 37,482
Short Long Term Debt Total 163,985



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
80,066
82,432
87,869
74,075
49,592
46,405
43,127
37,683
32,006
36,952
0
20,095
22,276
37,634
37,367
32,005
43,370
45,665
55,928
51,724
67,754
58,207
56,260
69,943
63,058
63,209
59,697
54,812
133,338
140,457
145,242
164,331
199,379
210,432
209,697
223,936
245,446
224,106
233,988
241,593
255,634
335,220
356,646
374,932
419,116
419,116
412,023
345,637
350,552
350,552
393,898
382,323
422,996
425,797
429,805
436,467
436,467429,805425,797422,996382,323393,898350,552350,552345,637412,023419,116419,116374,932356,646335,220255,634241,593233,988224,106245,446223,936209,697210,432199,379164,331145,242140,457133,33854,81259,69763,20963,05869,94356,26058,20767,75451,72455,92845,66543,37032,00537,36737,63422,27620,095036,95232,00637,68343,12746,40549,59274,07587,86982,43280,066000
   > Total Current Assets 
0
0
0
40,934
45,588
54,752
40,056
38,897
33,832
26,785
22,452
17,058
22,066
0
8,652
11,174
25,069
27,204
22,272
33,968
36,673
47,054
43,765
59,758
51,327
48,891
62,631
55,859
55,797
51,529
46,014
65,405
70,641
69,912
86,487
105,875
116,431
121,952
134,264
132,052
114,197
115,081
111,367
119,302
197,325
219,750
232,020
263,632
263,632
251,258
208,804
220,085
220,085
256,980
252,048
266,056
277,500
278,573
291,737
291,737278,573277,500266,056252,048256,980220,085220,085208,804251,258263,632263,632232,020219,750197,325119,302111,367115,081114,197132,052134,264121,952116,431105,87586,48769,91270,64165,40546,01451,52955,79755,85962,63148,89151,32759,75843,76547,05436,67333,96822,27227,20425,06911,1748,652022,06617,05822,45226,78533,83238,89740,05654,75245,58840,934000
       Cash And Cash Equivalents 
0
0
0
22,814
28,608
39,635
22,897
13,701
20,450
14,339
11,860
4,895
10,535
0
1,886
6,974
23,182
16,977
17,139
23,431
25,581
35,820
29,987
41,569
32,623
27,790
39,216
34,595
31,173
23,820
18,807
33,538
29,235
28,595
45,075
70,371
72,070
75,776
82,531
91,868
73,292
72,638
68,892
74,266
147,610
171,829
181,738
205,486
205,486
188,385
158,037
169,335
169,335
189,964
188,703
184,780
207,342
192,373
54,653
54,653192,373207,342184,780188,703189,964169,335169,335158,037188,385205,486205,486181,738171,829147,61074,26668,89272,63873,29291,86882,53175,77672,07070,37145,07528,59529,23533,53818,80723,82031,17334,59539,21627,79032,62341,56929,98735,82025,58123,43117,13916,97723,1826,9741,886010,5354,89511,86014,33920,45013,70122,89739,63528,60822,814000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-737
-519
-662
-568
-700
-989
0
0
0
0
0
0
0
0
0
0
0
142,912
142,91200000000000-989-700-568-662-519-73700000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
3,277
241
306
329
830
388
0
369
538
859
7,085
606
849
807
1,775
2,115
1,715
2,571
4,774
4,652
3,272
4,394
6,173
6,588
11,975
21,208
21,329
20,283
12,217
17,717
19,395
27,388
18,304
25,585
27,997
29,524
26,277
33,710
29,676
31,049
31,936
31,936
37,568
28,285
26,454
26,454
32,878
28,828
32,931
27,619
33,158
40,521
40,52133,15827,61932,93128,82832,87826,45426,45428,28537,56831,93631,93631,04929,67633,71026,27729,52427,99725,58518,30427,38819,39517,71712,21720,28321,32921,20811,9756,5886,1734,3943,2724,6524,7742,5711,7152,1151,7758078496067,08585953836903888303293062413,2770000000
       Other Current Assets 
0
0
0
1,994
1,828
1,463
1,912
9,932
584
684
919
2,804
1,161
0
1,298
668
-2,838
247
618
2,008
0
0
0
144
0
0
0
227
0
0
0
974
0
0
0
1,077
0
0
0
1,813
0
0
0
2,279
0
0
0
4,081
4,081
830
846
200
200
209
1,011
218
213
0
212
21202132181,0112092002008468304,0814,0810002,2790001,8130001,0770009740002270001440002,008618247-2,8386681,29801,1612,8049196845849,9321,9121,4631,8281,994000
   > Long-term Assets 
0
0
0
39,133
36,844
33,116
34,020
10,694
12,573
16,342
15,231
14,948
14,886
0
11,443
11,102
9,727
10,163
9,733
9,402
8,992
8,873
7,960
7,995
6,880
7,369
7,312
7,199
7,412
8,168
8,798
67,933
69,816
75,330
77,845
93,504
94,001
87,745
89,672
113,394
109,909
118,907
130,227
136,333
137,895
136,896
142,912
155,484
155,484
160,765
136,833
130,467
130,467
136,918
130,275
156,940
148,297
151,232
144,730
144,730151,232148,297156,940130,275136,918130,467130,467136,833160,765155,484155,484142,912136,896137,895136,333130,227118,907109,909113,39489,67287,74594,00193,50477,84575,33069,81667,9338,7988,1687,4127,1997,3127,3696,8807,9957,9608,8738,9929,4029,73310,1639,72711,10211,443014,88614,94815,23116,34212,57310,69434,02033,11636,84439,133000
       Property Plant Equipment 
0
0
0
7,508
6,976
6,348
7,377
8,913
9,350
13,189
12,416
12,400
12,405
0
9,326
9,427
8,858
8,761
8,906
8,600
8,238
8,169
7,329
6,807
5,836
6,302
6,257
6,189
6,379
6,535
6,629
6,355
6,884
8,127
9,176
9,878
9,826
9,586
9,642
9,611
13,664
17,080
16,151
16,278
15,739
15,781
19,386
21,687
21,687
37,646
32,669
29,262
29,262
29,958
27,782
40,772
39,145
39,346
37,482
37,48239,34639,14540,77227,78229,95829,26229,26232,66937,64621,68721,68719,38615,78115,73916,27816,15117,08013,6649,6119,6429,5869,8269,8789,1768,1276,8846,3556,6296,5356,3796,1896,2576,3025,8366,8077,3298,1698,2388,6008,9068,7618,8589,4279,326012,40512,40012,41613,1899,3508,9137,3776,3486,9767,508000
       Goodwill 
0
0
0
6,178
5,789
4,784
2,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-9,867
-9,867
0
-1,438
5,905
0
6,137
3,779
3,7796,13705,905-1,4380-9,867-9,867000000000000000000000000000000000000000000002,0164,7845,7896,178000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,682
5,796
5,722
6,104
8,630
8,787
7,403
11,631
10,776
9,731
9,767
9,650
9,239
9,2399,6509,7679,73110,77611,6317,4038,7878,6306,1045,7225,7965,6820000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
25,195
23,844
21,770
24,387
1,547
1,580
1,556
1,400
0
1,258
0
0
708
0
0
0
559
0
0
0
945
0
0
0
792
0
0
0
59,610
0
0
0
67,940
0
0
0
59,981
0
0
0
79,318
0
0
0
94,233
94,233
0
0
83,834
83,834
0
71,561
69,701
75,121
67,276
66,070
66,07067,27675,12169,70171,561083,83483,8340094,23394,23300079,31800059,98100067,94000059,610000792000945000559000708001,25801,4001,5561,5801,54724,38721,77023,84425,195000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,838
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,815
0
0
18,802
18,451
21,229
19,563
21,594
24,300
30,795
28,823
0
028,82330,79524,30021,59419,56321,22918,45118,8020030,8150000000000000000000000000000002,8380000000000000000
> Total Liabilities 
0
0
0
60,992
74,575
74,008
49,632
36,159
34,723
37,213
34,688
33,545
41,694
0
34,360
32,396
45,362
38,145
34,155
36,452
35,885
39,297
31,573
31,464
26,509
24,975
41,163
36,995
39,371
39,500
38,004
104,451
109,531
137,504
157,037
176,822
171,463
162,680
167,959
174,809
146,544
145,882
142,604
138,376
207,699
213,173
214,963
235,389
235,389
213,865
178,786
180,341
180,341
194,228
182,069
223,653
221,159
229,433
226,525
226,525229,433221,159223,653182,069194,228180,341180,341178,786213,865235,389235,389214,963213,173207,699138,376142,604145,882146,544174,809167,959162,680171,463176,822157,037137,504109,531104,45138,00439,50039,37136,99541,16324,97526,50931,46431,57339,29735,88536,45234,15538,14545,36232,39634,360041,69433,54534,68837,21334,72336,15949,63274,00874,57560,992000
   > Total Current Liabilities 
0
0
0
51,966
66,014
62,727
25,454
12,879
10,719
9,676
9,677
10,544
18,931
0
13,147
11,860
26,279
19,354
14,297
17,848
18,218
22,460
16,765
18,086
15,255
13,976
15,649
14,732
18,550
20,537
20,517
54,034
65,817
39,421
65,908
70,216
72,889
74,428
100,265
94,485
69,928
75,011
98,582
114,130
48,969
49,362
42,858
76,969
76,969
47,838
40,277
41,265
41,265
49,194
46,694
59,003
59,698
64,952
68,058
68,05864,95259,69859,00346,69449,19441,26541,26540,27747,83876,96976,96942,85849,36248,969114,13098,58275,01169,92894,485100,26574,42872,88970,21665,90839,42165,81754,03420,51720,53718,55014,73215,64913,97615,25518,08616,76522,46018,21817,84814,29719,35426,27911,86013,147018,93110,5449,6779,67610,71912,87925,45462,72766,01451,966000
       Short-term Debt 
0
0
0
39,402
48,689
42,092
15,148
0
0
0
0
1,579
5,536
0
1,207
1,184
13,463
9,326
3,959
1,058
670
644
586
761
329
237
2,270
3,619
4,870
6,195
6,613
27,764
33,581
12,920
20,165
26,663
34,798
40,972
42,049
40,606
39,559
40,486
39,968
53,248
1,813
1,740
2,048
4,008
4,008
4,624
3,894
3,792
3,792
4,120
3,950
5,749
5,233
5,653
5,518
5,5185,6535,2335,7493,9504,1203,7923,7923,8944,6244,0084,0082,0481,7401,81353,24839,96840,48639,55940,60642,04940,97234,79826,66320,16512,92033,58127,7646,6136,1954,8703,6192,2702373297615866446701,0583,9599,32613,4631,1841,20705,5361,579000015,14842,09248,68939,402000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,661
2,607
1,657
1,657
1,657
1,844
1,728
1,627
1,768
1,805
1,797
1,748
1,7481,7971,8051,7681,6271,7281,8441,6571,6571,6572,6071,66100000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
11,280
9,471
0
0
0
0
0
0
0
0
7,560
1,489
5,754
3,556
4,765
5,561
9,791
4,478
7,446
3,579
9,301
9,061
8,979
1,111
10,515
11,340
10,898
5,944
18,040
17,161
19,997
11,313
35,714
30,933
36,216
7,598
29,306
33,471
37,491
5,994
46,993
47,414
40,648
13,491
13,491
43,142
36,337
37,473
37,473
45,074
42,744
53,254
54,465
59,299
62,540
62,54059,29954,46553,25442,74445,07437,47337,47336,33743,14213,49113,49140,64847,41446,9935,99437,49133,47129,3067,59836,21630,93335,71411,31319,99717,16118,0405,94410,89811,34010,5151,1118,9799,0619,3013,5797,4464,4789,7915,5614,7653,5565,7541,4897,560000000009,47111,2800000
       Other Current Liabilities 
0
0
0
12,564
6,045
5,216
10,307
12,879
10,719
9,676
9,677
8,965
13,395
0
3,411
6,627
4,583
2,393
2,604
8,191
4,731
14,337
5,941
11,071
3,242
2,203
1,917
7,590
664
547
599
19,334
13,258
8,413
24,800
31,275
1,387
1,598
21,070
45,366
165
144
20,249
20,278
163
208
162
25,219
25,219
71
46
44
44
0
4,031
5,300
56
5,180
5,219
5,2195,180565,3004,03104444467125,21925,21916220816320,27820,24914416545,36621,0701,5981,38731,27524,8008,41313,25819,3345995476647,5901,9172,2033,24211,0715,94114,3374,7318,1912,6042,3934,5836,6273,411013,3958,9659,6779,67610,71912,87910,3075,2166,04512,564000
   > Long-term Liabilities 
0
0
0
9,026
8,561
11,281
24,178
23,280
24,004
27,537
25,011
23,002
22,763
0
21,213
20,536
19,082
18,792
19,858
18,604
17,667
16,837
14,808
13,379
11,254
10,998
25,514
22,263
20,820
18,963
17,487
50,416
43,714
98,083
91,129
106,606
98,575
88,252
67,694
80,324
76,616
70,871
44,022
24,246
158,729
163,812
172,106
158,420
158,420
166,027
138,509
139,076
139,076
145,034
135,375
164,650
161,461
164,481
158,467
158,467164,481161,461164,650135,375145,034139,076139,076138,509166,027158,420158,420172,106163,812158,72924,24644,02270,87176,61680,32467,69488,25298,575106,60691,12998,08343,71450,41617,48718,96320,82022,26325,51410,99811,25413,37914,80816,83717,66718,60419,85818,79219,08220,53621,213022,76323,00225,01127,53724,00423,28024,17811,2818,5619,026000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
173
161
159
333
146
162
152
143
0
0
0
0
000014315216214633315916117300000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,443
0
0
0
266
0
0
0
0
0
0
0
00000002660004,44300000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
19,074
7,858
13,860
16,773
14,449
11,682
5,914
2,995
-1,540
-4,742
0
-14,265
-10,120
-7,727
-778
-2,150
6,918
9,780
16,631
20,152
36,289
31,698
31,285
28,779
26,063
23,838
20,197
16,808
28,887
30,926
7,738
7,294
22,557
38,968
47,017
55,977
70,637
77,562
88,106
98,989
117,258
127,522
143,473
159,968
183,727
183,727
198,158
166,851
170,211
170,211
199,670
200,254
199,343
204,638
200,372
209,942
209,942200,372204,638199,343200,254199,670170,211170,211166,851198,158183,727183,727159,968143,473127,522117,25898,98988,10677,56270,63755,97747,01738,96822,5577,2947,73830,92628,88716,80820,19723,83826,06328,77931,28531,69836,28920,15216,6319,7806,918-2,150-778-7,727-10,120-14,2650-4,742-1,5402,9955,91411,68214,44916,77313,8607,85819,074000
   Common Stock
0
0
0
110,681
103,708
14,863
19,559
23,208
26,043
26,703
26,627
26,447
29,961
0
11,410
13,347
1,692
2,735
3,102
4,620
5,146
5,531
5,173
4,958
4,419
4,578
4,594
4,504
4,675
4,589
4,629
4,792
5,118
5,536
6,107
6,946
7,418
7,057
7,172
7,109
6,987
7,114
6,885
7,072
7,004
7,172
7,492
7,857
7,857
7,254
6,258
6,425
6,425
7,469
7,482
7,518
7,509
7,540
7,650
7,6507,5407,5097,5187,4827,4696,4256,4256,2587,2547,8577,8577,4927,1727,0047,0726,8857,1146,9877,1097,1727,0577,4186,9466,1075,5365,1184,7924,6294,5894,6754,5044,5944,5784,4194,9585,1735,5315,1464,6203,1022,7351,69213,34711,410029,96126,44726,62726,70326,04323,20819,55914,863103,708110,681000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-6,636
0
0
0
-6,796
0
0
0
-7,569
0
0
0
18,706
18,208
18,595
19,388
20,539
20,662
20,700
20,969
44
45
44
47
72
71
73
72
63
43
-700
-494
-1,125
-2,911
-1,270
-985
1,884
1,729
1,998
1,277
4,165
4,144
4,284
4,980
5,339
5,339
14,671
8,504
1,917
1,917
-12,607
-24,145
-4,906
-8,737
-6,037
-10,915
-10,915-6,037-8,737-4,906-24,145-12,6071,9171,9178,50414,6715,3395,3394,9804,2844,1444,1651,2771,9981,7291,884-985-1,270-2,911-1,125-494-7004363727371724744454420,96920,70020,66220,53919,38818,59518,20818,706000-7,569000-6,796000-6,636000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
204,766
-95,850
-1,003
-2,786
241,423
-14,361
-20,789
-23,632
244,389
-34,704
0
313,101
231,866
236,909
243,270
245,885
254,901
272,491
281,216
282,261
282,260
282,385
282,428
281,841
283,396
283,517
283,528
283,538
301,876
308,320
310,907
316,858
370,220
381,042
387,760
391,023
387,525
387,956
389,310
391,151
392,266
394,255
396,033
396,231
396,799
396,799
380,856
390,928
399,850
399,850
458,357
459,450
463,222
462,297
464,363
475,983
475,983464,363462,297463,222459,450458,357399,850399,850390,928380,856396,799396,799396,231396,033394,255392,266391,151389,310387,956387,525391,023387,760381,042370,220316,858310,907308,320301,876283,538283,528283,517283,396281,841282,428282,385282,260282,261281,216272,491254,901245,885243,270236,909231,866313,1010-34,704244,389-23,632-20,789-14,361241,423-2,786-1,003-95,850204,766000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue218,720
Cost of Revenue-24,368
Gross Profit194,353194,352
 
Operating Income (+$)
Gross Profit194,353
Operating Expense-243,220
Operating Income-24,499-48,867
 
Operating Expense (+$)
Research Development68,179
Selling General Administrative148,108
Selling And Marketing Expenses-
Operating Expense243,220216,287
 
Net Interest Income (+$)
Interest Income7,162
Interest Expense-6,001
Other Finance Cost-10,029
Net Interest Income-8,868
 
Pretax Income (+$)
Operating Income-24,499
Net Interest Income-8,868
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-28,063-29,803
EBIT - interestExpense = -6,001
-22,055
-16,054
Interest Expense6,001
Earnings Before Interest and Taxes (EBIT)--22,062
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-28,063
Tax Provision--6,008
Net Income From Continuing Ops-22,055-22,055
Net Income-22,055
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net5,3048,868
 

Technical Analysis of Pharming
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharming. The general trend of Pharming is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharming's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharming Group NV.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 11.94 < 12.20 < 13.20.

The bearish price targets are: 10.71 > 10.38 > 10.

Tweet this
Pharming Group NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharming Group NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharming Group NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharming Group NV. The current macd is -0.18294499.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharming price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharming. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharming price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pharming Group NV Daily Moving Average Convergence/Divergence (MACD) ChartPharming Group NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharming Group NV. The current adx is 16.15.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharming shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Pharming Group NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharming Group NV. The current sar is 12.20.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharming Group NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharming Group NV. The current rsi is 42.90. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Pharming Group NV Daily Relative Strength Index (RSI) ChartPharming Group NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharming Group NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharming price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pharming Group NV Daily Stochastic Oscillator ChartPharming Group NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharming Group NV. The current cci is -148.55980844.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pharming Group NV Daily Commodity Channel Index (CCI) ChartPharming Group NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharming Group NV. The current cmo is -20.02353193.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharming Group NV Daily Chande Momentum Oscillator (CMO) ChartPharming Group NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharming Group NV. The current willr is -89.21330089.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pharming Group NV Daily Williams %R ChartPharming Group NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharming Group NV.

Pharming Group NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharming Group NV. The current atr is 0.44616429.

Pharming Group NV Daily Average True Range (ATR) ChartPharming Group NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharming Group NV. The current obv is 629,804.

Pharming Group NV Daily On-Balance Volume (OBV) ChartPharming Group NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharming Group NV. The current mfi is 25.47.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pharming Group NV Daily Money Flow Index (MFI) ChartPharming Group NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharming Group NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Pharming Group NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.900
Ma 20Greater thanMa 5011.273
Ma 50Greater thanMa 10011.715
Ma 100Greater thanMa 20011.739
OpenGreater thanClose10.800
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharming with someone you think should read this too:
  • Are you bullish or bearish on Pharming? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharming? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.


Comments

How you think about this?

Leave a comment

Stay informed about Pharming Group NV.

Receive notifications about Pharming Group NV in your mailbox!